Australian biotech market watch 05/03/10
Friday, 05 March, 2010
Not even an interest rate rise could put a dampener on the stock market this week, with the All Ordinaries up by 125 points, or 2.7 per cent, from Monday.
In contrast, the life sciences index has been a little more turbulent, slipping through to Thursday before a rebound in trading this morning to 8,733.
The lion's share of the rebound is due to the biotech gorilla, CSL (ASX:CSL), bumping up 66c, or 1.9 per cent, to $35.45, following news that CSL's subsidiary, CSL Behring, has been given the go ahead by the US Food and Drug Administration to market a new blood plasma product.
ResMed (ASX:RMD) also saw an 8c lift to $6.60.
The rest of the market has been relatively steady, although Primary Health Care did take an 11c dip to $4.15.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
